For Investors

Abscopal Therapeutics is developing a new class of precision oncology medicines designed to trigger systemic anti-tumor immunity and extend therapeutic activity beyond the directly treated tumor. Our lead program targets a previously underexploited cancer-signaling vulnerability with the potential to enhance responses to PARP inhibitors, overcome treatment resistance, and expand the number of patients who benefit from these important therapies.